AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Ratio Therapeutics closes $70 million Series C financing to advance clinical development and expand manufacturing infrastructure.
PRIVATEJul 31, 2026•about 2 months ago
Amount Raised
$70 Million
Round Type
Series C
BostonBiotechnologyTherapeuticsPharmaceutical
Investors
Wasatch GroupEli Lilly And CompanyCatalio Capital ManagementBristol Myers SquibbDuquesne Family Office
Description
Ratio Therapeutics, Inc. announced the closing of a $70 million Series C financing. The financing included participation from both existing and new investors. Proceeds will be used to advance the ATLAS study and expand the company's pipeline and manufacturing capabilities
Company Information
Company
Ratio Therapeutics
Location
Boston, Massachusetts, United States
About
Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. The company maintains a strong commitment to manufacturing through its collaboration with PharmaLogic and its own state-of-the-art facility located in Salt Lake City, Utah, ensuring reliable supply and quality in radiopharmaceutical production. Ratio plans to initiate a Phase 1/2 trial to evaluate the safety, tolerability and efficacy of its FAP-targeted radiotherapeutic as a treatment for patients with relapsed or refractory soft tissue sarcoma. The company is also advancing other programs in its pipeline, including the pre-clinical assessment of [Lu-177]-RTX2358 across several cancer indications to explore its broader therapeutic potential and expects its Granzyme B-targeted agent for PET imaging program to move into the clinic in 2026.
Fundz sees it the moment Ratio Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BostonBiotechnologyTherapeuticsPharmaceutical